Indeed, the A3R agonists CL-IBMECA and CF102 have shown promise in vitro by inducing apoptosis in multiple tumor types through the suppression of PKA, ERK, and AKT pathways [80,97,98,99]. This evidence concerns the gene AKT1 and neoplasm.